Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

Any small benefits to the pharmaceutical industry from Brexit would be “hugely outweighed” by additional costs or lack of access to existing medicines markets, according to a report by a cross-party group of MPs.

The select committee's report warned that global manufacturers are unlikely to prioritise the UK over the much bigger EU medicines market post-Brexit